Paul Andrew Antony
Affiliation: National Institutes of Health
- Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?Paul Andrew Antony
Surgery Branch, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Immunother 25:202-6. 2002..The challenge for immunotherapists now is to overcome immunosuppression using the knowledge gained through the understanding of T regulatory cell function...
- CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2Paul Andrew Antony
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892, USA
J Immunother 28:120-8. 2005..The authors propose that other gamma c-signaling cytokines, including IL-15, may be alternative choices for the immunotherapy of cancer...